



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board MEETING AGENDA

May 7, 2024

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Liza Claus, PharmD (Chair)	Jeffrey Taylor, PharmD (HCPF)
Brian Jackson, MD, MA (Vice Chair)	Veronia Garcia, PharmD (HCPF)
Todd Brubaker, DO	Rachele Poissant, PharmD (HCPF)
Shilpa Klocke, PharmD	Julia Rawlings, PharmD (CO-DUR)
Patricia Lanus, BSP Pharm, MHA	Robert L Page II, PharmD, MSPH (CO-DUR)
Kenneth MacIntyre, DO	Gina Moore, PharmD, MBA (CO-DUR)
Ingrid Pan, PharmD	Heather Anderson, PhD (CO-DUR)
	Garth Wright, MPH (CO-DUR)
	Nicholas Mendola, MPH (CO-DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the February 13, 2024 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist no later than 24 hours prior to the start of the meeting

7. Clinical Updates and General Orders

- FDA New Product & Safety Updates
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

8. New Business (open for public testimony and DUR Board review)**A. Review of Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes**

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Phosphodiesterase Inhibitors (PDEIs), Endothelin Receptor Antagonists, Prostacyclin Analogues and Receptor Agonists, Guanylate Cyclase Stimulators
- Statins & Combinations
- Movement Disorder Agents
- Acne Agents, Topical,
- Anti-Psoriatics - Oral & Topical
- Immunomodulators, Topical
- Atopic Dermatitis, Antineoplastics & Other Agents
- *H. Pylori* Treatments
- Proton Pump Inhibitors

Mass review drug classes*

- Tetracyclines
- Alpha-Blockers
- Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
- Calcium Channel Blockers - Dihydropyridines (DHPs) & Non-DHPs
- Angiotensin Converting Enzyme (ACE) Inhibitors & Combinations
- Angiotensin Receptor Blockers (ARBs) & Combinations
- Renin Inhibitors & Combinations
- Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
- Acne Agents, Oral Isotretinoin
- Rosacea Agents
- Topical Steroids - Low, Medium, High & Very High Potency
- Anti-Emetics - Oral & Non-Oral
- GI Motility, Chronic
- Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
- Pancreatic Enzymes
- Non-Biologic Ulcerative Colitis - Oral & Rectal
- Anticoagulants - Oral & Parenteral
- Anti-Platelets
- Colony Stimulating Factors
- Erythropoiesis Stimulating Agents

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

B. Review of Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDL> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial review of newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization)

- Rezdifra (resmetirom)
- Wegovy (semaglutide) review of proposed criteria for reducing risk of major CV events indication
- Jesduvroq (daprodustat)

- Rivfloza (nedosiran)
- Sohonos (palovarotene)
- Filsuvez (birch triterpenes)
- Proposed Compound Claims Cost Ceiling Policy
- Proposed Additions to OTC Product Coverage
- Maximum Dose for Buprenorphine-Containing Products Used to Treat OUD

9. Adjournment

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

Improving health care equity, access, and outcomes for the people we serve while
saving Coloradans money on health care and driving value for Colorado.
www.colorado.gov/hcpf

